menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

IGMS / IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Call Transcript

IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Call Transcript
IGM Biosciences, Inc. (NASDAQ:IGMS ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Fred Schwarzer – Chief Executive Officer Misbah Tahir – Chief Financial Officer Chris Takimoto – Chief Medical Officer Mary Beth Harler – President-IGM Autoimmunity and Inflammation Bruce Keyt – Chief Scientific Officer Conference Call Participants Stephen Willey – Stifel Greg Harrison – Bank of America Michael Schmidt – Guggenheim Roger Song – Jefferies Joel Beatty – Baird Noah Eisenberg – JPMorgan Leonid Timashev – RBC Capital Markets Asthika Goonewardene – Truist Operator Good day, everyone, and welcome to the IGM Biosciences' Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today's call is being recorded. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Biosciences

Inc

IGMS

2022

Earnings

Call

Transcript

Biosciences

igms

Stock

Posted: Mar 31 2023, 23:06
Author Name: Seeking Alpha
Views: 083056

IGMS News  

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

By PRNewsWire
October 25, 2023

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ph more_horizontal

Medivir to present at the Pareto Securities Healthcare Conference

By PRNewsWire
September 14, 2023

Medivir to present at the Pareto Securities Healthcare Conference

STOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innova more_horizontal

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

By PRNewsWire
September 1, 2023

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

STOCKHOLM , Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo more_horizontal

Medivir to present at the Erik Penser Bank Company Event

By PRNewsWire
August 23, 2023

Medivir to present at the Erik Penser Bank Company Event

STOCKHOLM , Aug. 23, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo more_horizontal

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 3, 2023

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $1. more_horizontal

Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?

By Zacks Investment Research
June 23, 2023

Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?

IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might more_horizontal

Medivir to present at the Redeye Growth Day

By PRNewsWire
June 1, 2023

Medivir to present at the Redeye Growth Day

STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for more_horizontal

Medivir to present at the ABGSC Life Science Summit

By PRNewsWire
May 30, 2023

Medivir to present at the ABGSC Life Science Summit

STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2026 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: